Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-trastuzumab PET/CT to guide T-DM1 sequencing in advanced HER2-positive breast cancer
2024-516253-49-01Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab emtansine and 89Zr-trastuzumab in breast cancer, sponsored by Institut Jules Bordet. Primary endpoints: Characterization of genomic alterations and HER2 expression and Time to treatment failure. Started Sep 2025; status: completed.
02
Drugs
trastuzumab emtansine89Zr-trastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-516253-49-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516253-49-01.